Search results for "Valence"

showing 10 items of 2732 documents

Fear of cancer progression in patients with stage IA malignant melanoma.

2018

We aimed to determine the prevalence and importance of fear of cancer progression (FoP) in melanoma patients with stage IA tumours to assess psychosocial and demographic factors associated with severity of FoP and to determine the relationship of FoP and quality of life (QoL). One hundred and thirty-six patients with stage IA melanoma completed the short version of the Fear of Progression Questionnaire (FoP-Q-SF), the Hospital Anxiety and Depression Scale (HADS) and the EORTC-QLQ-C30. We found a mean FoP-Q-SF sum score of 30.2 points (±8.4 points SD). In this study, 33% of patients reported high FoP at or above the cutoff-value of 34 points. Higher FoP was found in women (p < 0.01), young (…

OncologyAdultMalemedicine.medical_specialtyMedizinAnxietyHospital Anxiety and Depression Scale03 medical and health sciences0302 clinical medicineQuality of lifeRisk FactorsInternal medicinemedicinePrevalenceHumans030212 general & internal medicineStage (cooking)MelanomaDepression (differential diagnoses)AgedAged 80 and overPsychiatric Status Rating Scalesbusiness.industryCancerFearMiddle Agedmedicine.diseasehumanitiesLogistic ModelsOncologyPhobic Disorders030220 oncology & carcinogenesisDisease ProgressionQuality of LifeAnxietyFemaleSkin cancermedicine.symptombusinessPsychosocialEuropean journal of cancer care
researchProduct

The prevalence of human papilloma virus (HPV) infections in oral squamous cell carcinomas: a retrospective analysis of 88 patients and literature ove…

2014

In addition to tobacco and alcohol consumption, the two main risk factors for oral squamous cell carcinoma (OSCC), recent studies have revealed infections with human papilloma virus (HPV) as an additional risk factor for OSCC development. In the field of head and neck malignancies, the prevalence of HPV infections in oropharyngeal cancer (OC) ranges in different studies up to 84%. While HPV infection is discussed as an independent risk factor in this region, its distinguished role in carcinogenesis of tumours localized to the oral cavity remains still uncertain. In this study, we analysed the HPV status in 88 consecutive patients with OSCCs localized anterior of the palatoglossal arch who w…

OncologyAdultMalemedicine.medical_specialtyPathologyAlcohol DrinkingCarcinogenesisCellAlphapapillomavirusmedicine.disease_causePalatine tonsilYoung AdultSex FactorsInternal medicineGermanyPrevalenceMedicineHumansRisk factorAgedNeoplasm StagingRetrospective StudiesHuman papilloma virusAged 80 and overHuman papillomavirus 16Human papillomavirus 18business.industryPapillomavirus InfectionsSmokingHPV infectionAge Factorsvirus diseasesCancerMiddle Agedmedicine.diseasestomatognathic diseasesOropharyngeal Neoplasmsmedicine.anatomical_structureOtorhinolaryngologyOral and maxillofacial surgeryCarcinoma Squamous CellSurgeryFemaleMouth NeoplasmsOral SurgerybusinessCarcinogenesisJournal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
researchProduct

Distribution of human papillomavirus types in women from Valencia, Spain, with abnormal cytology.

2010

Objective To determine human papillomavirus (HPV) types among cervical smears using polymerase chain reaction (PCR) and to contribute to the knowledge of human papillomavirus genotype distribution and prevalence of oncogenic types in cervical lesions in Spain. Study Design Consensus PCR and direct sequencing of PCR products (DNA HPV typing) were used in a retrospective study to determinate the type or types of HPV on 974 cytology smears of women with abnormal cytology results. Results Of 974 smears, 79.8% were high-risk (H-R) HPVs, 19.7% low-risk (L-R) HPVs, 4.6% indeterminate-risk (I-R) HPVs, considering both single and multiple infections. Multiple infections were detected in 4.7% of the …

OncologyAdultmedicine.medical_specialtyHistologyGenotypeCost effectivenessPopulationPrevalenceUterine Cervical NeoplasmsAlphapapillomavirusCervical intraepithelial neoplasiaPolymerase Chain ReactionPathology and Forensic MedicineGene FrequencyCytologyInternal medicineGenotypemedicinePrevalenceHumansMass ScreeningeducationMass screeningRetrospective StudiesGynecologyVaginal Smearseducation.field_of_studyHuman papillomavirus 16Human papillomavirus 18business.industryPapillomavirus Infectionsvirus diseasesGeneral Medicinemedicine.diseaseUterine Cervical Dysplasiafemale genital diseases and pregnancy complicationsSquamous intraepithelial lesionSpainDNA ViralFemalebusinessActa cytologica
researchProduct

Potential impact of a nonavalent HPV vaccine on HPV related low-and high-grade cervical intraepithelial lesions: A referral hospital-based study in S…

2017

ABSTRACT While bivalent and quadrivalent HPV vaccines have been used for about 10 years, a nonavalent vaccine against HPV types 6/11/16/18/31/33/45/52 and 58 has been recently approved by FDA and EMA and is now commercially available. The objective of our study was to evaluate the potential impact of the nonavalent vaccine on HPV infection and related low- and high-grade squamous intraepithelial lesions (LSIL, HSIL), compared to the impact of the quadrivalent vaccine, in a female population living in Sicily (Italy). Low estimates of HPV vaccine impact were calculated as prevalence of HPV 6/11/16/18/31/33/45/52 and 58 genotypes, alone or in association, but excluding presence of other HPV ty…

OncologyAdultmedicine.medical_specialtyReferralGenotypeImmunologyUterine Cervical NeoplasmsHPV vaccinesCervix UteriHospital based study03 medical and health sciences0302 clinical medicineHuman Papillomavirus Recombinant Vaccine Quadrivalent Types 6 11 16 18Internal medicinevaccineGenotypemedicinePrevalenceHumansImmunology and Allergy030212 general & internal medicinePapillomavirus VaccinesquadrivalentReferral and ConsultationSicilyFemale populationsquamous intraepithelial lesionGynecologyPharmacologyPotential impactHpv typesbusiness.industryPapillomavirus InfectionsHPV infectionsquamous intraepithelial lesionsvirus diseasesmedicine.diseaseUterine Cervical DysplasiaResearch Papersimpact estimateHPV infection; impact estimate; nonavalent; quadrivalent; squamous intraepithelial lesions; vaccine; Immunology and Allergy; Immunology; Pharmacology030220 oncology & carcinogenesisHPV infectionFemalebusinessnonavalent
researchProduct

Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer

2019

Background The role of the BARD1 gene in breast cancer (BC) and ovarian cancer (OC) predisposition remains elusive, as published case-control investigations have revealed controversial results. We aimed to assess the role of deleterious BARD1 germline variants in BC/OC predisposition in a sample of 4920 BRCA1/2-negative female BC/OC index patients of the German Consortium for Hereditary Breast and Ovarian Cancer (GC-HBOC). Methods A total of 4469 female index patients with BC, 451 index patients with OC, and 2767 geographically matched female control individuals were screened for loss-of-function (LoF) mutations and potentially damaging rare missense variants in BARD1. All patients met the …

OncologyGermline0302 clinical medicineLoss of Function MutationSurgical oncologyOdds RatioPrevalenceMissense mutation030212 general & internal medicineAge of Onset10. No inequalityExomeEarly onset breast cancerAged 80 and overOvarian NeoplasmsBARD1 GeneHigh-Throughput Nucleotide SequencingMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good health030220 oncology & carcinogenesisFemaleTechnology PlatformsResearch ArticleAdultmedicine.medical_specialtyAdolescentUbiquitin-Protein Ligases610Breast Neoplasmslcsh:RC254-282Young Adult03 medical and health sciencesGermline mutationBreast cancerOvarian cancerInternal medicinemedicineBARD1HumansGenetic Predisposition to DiseaseGermline mutationsGenetic Association StudiesGerm-Line MutationAgedbusiness.industryTumor Suppressor ProteinsOdds ratiomedicine.diseaseConfidence intervalBARD1; Early onset breast cancer; Germline mutations; Ovarian cancerOvarian cancerbusiness
researchProduct

Papillary thyroid microcarcinoma: extrathyroidal extension, lymph node metastases and risk factors for recurrence in a high prevalence of goiter area

2010

BACKGROUND. Papillary thyroid microcarcinoma (PTMC) is diagnosed with increasing frequency. Since risk factors for an aggressive clinical behavior have not been clearly delineated, the best therapeutic option and follow up protocol for PTMC have not been established yet, especially in case of incidental diagnosis after partial thyroidectomy for benign disease. We reviewed our series of patients with PMTC to determine risk factors for recurrence in a high prevalence of goiter area. METHODS. The medical records of all the patients who underwent total thyroidectomy (TT) with a final pathology report of PTMC between October 2002 and June 2007 were reviewed. Demographic, clinical and pathologica…

OncologyMaleGoiterendocrine system diseasesmedicine.medical_treatmentSettore MED/18 - CHIRURGIA GENERALEPapillaryPapillary thyroid cancerRisk Factors80 and overPrevalenceMedicineChildLymph nodeThyroid cancerAged 80 and overGoiterThyroidMiddle AgedPrognosismicrocarcinoma thyroid.medicine.anatomical_structureLocalItalyLymphatic MetastasisThyroidectomyFemaleRadiologyAdultendocrine systemmedicine.medical_specialtyAdolescentInternal medicineCarcinomaHumansNeoplasm InvasivenessThyroid NeoplasmsAgedCompletion thyroidectomyChi-Square Distributionbusiness.industryAdolescent; Adult; Aged; Aged; 80 and over; Carcinoma; Papillary; Chi-Square Distribution; Child; Female; Goiter; Humans; Italy; Linear Models; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence; Local; Prevalence; Prognosis; Risk Factors; Thyroid Neoplasms; ThyroidectomyCarcinomaThyroidectomymedicine.diseaseCarcinoma PapillaryNeoplasm RecurrenceLinear ModelsLymph Node ExcisionSurgeryNeoplasm Recurrence Localbusiness
researchProduct

Incidence, survival and prevalence of myeloid malignancies in Europe.

2012

Abstract Background The Surveillance of Rare Cancers in Europe (RARECARE) project aims at increasing knowledge of rare cancers in Europe. This manuscript describes the epidemiology of myeloid malignancies (MMs), taking into account the morphological characterisation of these tumours. Methods We used data gathered by RARECARE on cancer patients diagnosed from 1995 to 2002 and archived in 64 European population-based cancer registries, followed up to 31st December 2003 or later. Results The overall annual crude incidence of MMs was 8.6 per 100,000. Acute myeloid leukaemia (AML) and myeloproliferative neoplasms (MPN) were most common, with incidence rates of 3.7 and 3.1 per 100,000 year respec…

OncologyMyeloidMaleCancer ResearchMyeloidSurvivalChronic myelomonocytic leukaemiaCancer registry Incidence Prevalence Survival Myeloid malignancies Acute myeloid leukaemia Myelodysplastic syndrome Chronic myeloid leukaemia Chronic myelomonocytic leukaemiaImmunophenotypingEpidemiologyPrevalenceChildLeukemiaIncidence (epidemiology)IncidenceMyeloid malignanciesCancer registryMiddle AgedEuropeLeukemia Myeloid AcuteLeukemiamedicine.anatomical_structureOncologyChild PreschoolMyelodysplastic-Myeloproliferative Diseases/epidemiology/mortalityMyelodysplastic Syndromes/epidemiology/mortalityFemaleAdultmedicine.medical_specialtyAdolescentAcute myeloid leukaemiaNOEurope/epidemiologyInternal medicinemedicinecancer Incidence; survival and prevalence; myeloid malignanciesHumansPreschoolChronic myeloid leukaemiaddc:613AgedMyeloproliferative Disorders/epidemiology/mortalityMyeloproliferative Disordersbusiness.industryMyelodysplastic syndromesInfant NewbornCancerInfantcancer Incidencemedicine.diseaseNewbornMyelodysplastic-Myeloproliferative DiseasesCancer registrysurvival and prevalenceMyelodysplastic SyndromesImmunologyAcute/epidemiology/mortalitybusinessMyelodysplastic syndrome
researchProduct

Familial colorectal cancer risk: ESMO Clinical Practice Guidelines.

2010

OncologyRiskmedicine.medical_specialtyHeterozygoteColorectal cancermedicine.medical_treatmentColonoscopyAntineoplastic AgentsPenetranceGastroenterologyDNA Mismatch RepairInternal medicinemedicinePrevalenceHumansGenetic TestingRisk factorSigmoidoscopyColectomyColectomyGenetic testingRandomized Controlled Trials as Topicmedicine.diagnostic_testProctocolectomybusiness.industryIncidenceProctocolectomy RestorativeCancerSigmoidoscopyHematologyColonoscopymedicine.diseaseColorectal Neoplasms Hereditary NonpolyposisCombined Modality TherapyEuropeOncologybusinessFollow-Up StudiesAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Breakthrough pain in oncology: A longitudinal study

2010

Abstract Context Existing studies on breakthrough pain (BP) have reported different prevalence rates because of different settings, populations, and assessment methods. These studies have used cross-sectional designs, and the relationship of BP with analgesic treatment has not been evaluated. Objectives The aim of this study was to longitudinally assess BP in cancer patients admitted to oncology units. Methods A consecutive sample of patients admitted to oncology centers was selected. At admission (T0), three months after admission (T3), and six months after admission (T6), data on background pain and BP were recorded. BP was assessed in terms of its intensity, duration, number of episodes,…

Oncologybreakthrough pain; Cancer pain; epidemiology; oncology; Acute Disease; Aged; Analgesics; Female; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasms; Pain; Severity of Illness Index; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology (clinical); Nursing (all)2901 Nursing (miscellaneous)Malemedicine.medical_specialtyLongitudinal studyBreakthrough PainAnalgesicPrevalencePainContext (language use)Severity of Illness Indexlongitudinal study; breakthrough pain; cancer patientsInternal medicineNeoplasmsEpidemiologymedicineHumansLongitudinal StudiesStage (cooking)Cancer painGeneral NursingNursing (all)2901 Nursing (miscellaneous)AgedAnalgesicsbusiness.industrylongitudinal studyMiddle Agedbreakthrough painTreatment OutcomeAnesthesiology and Pain MedicineoncologyAcute DiseaseepidemiologyFemaleNeurology (clinical)cancer patientsbusinessCancer pain
researchProduct

Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review.

2014

Abstract Background/objectives Cachexia affects ∼80% of pancreatic cancer patients. An international consensus defines cachexia as an ongoing loss of skeletal muscle mass (sarcopenia) with or without loss of fat, which impairs body functioning and cannot be reversed by conventional nutritional measures. Weight loss percentage and elevated inflammation markers have been employed to define this condition earlier. This review aimed to assess the prevalence and consequences of cachexia and sarcopenia on survival in patients with pancreatic ductal adenocarcinoma. Methods The systematic review was performed by searching the articles with preset terms published in PubMed and Cochrane Database unti…

Oncologymedicine.medical_specialtySarcopeniaCachexiaEndocrinology Diabetes and MetabolismOverweightCachexiaWeight lossInternal medicinePancreatic cancerWeight LossmedicinePrevalenceHumansSarcopenic obesityHepatologybusiness.industryConfoundingGastroenterologymedicine.diseasePrognosismusculoskeletal systemPancreatic NeoplasmsSurvival RateCachexia/diagnosis/epidemiology/*etiology; Carcinoma Pancreatic Ductal/*complications/mortality; Humans; Pancreatic Neoplasms/*complications/mortality; Prevalence; Prognosis; Sarcopenia/diagnosis/epidemiology/*etiology; Survival Rate; Weight LossSarcopeniaAdenocarcinomamedicine.symptombusinessCarcinoma Pancreatic Ductal
researchProduct